Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

被引：25
|
作者：
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
机构：
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页码：S1314 / S1315
页数：2
相关论文
共 50 条
  • [31] EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected high-risk stage III melanoma: pembrolizumab crossover and rechallenge following recurrence
    Atkinson, Victoria
    Eggermont, Alexander M. M.
    Meshcheryakov, Andrey
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Barrow, Catherine
    Di Giacomo, Anna Maria
    Fisher, Rosalie
    Sandhu, Shahneen
    Kudchadkar, Ragini
    Ortiz Romero, Pablo Luis
    Svane, Inge Marie
    van Akkooi, Alexander
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 161 - 161
  • [32] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Giacomo, Anna Maria Di
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    van Akkooi, Alexander C. J.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
  • [33] Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
    Kennedy, Oliver John
    Kicinski, Michal
    Valpione, Sara
    Gandini, Sara
    Suciu, Stefan
    Blank, Christian U.
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Boers-Sonderen, Marye
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Robert, Caroline
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Mandala, Mario
    EUROPEAN JOURNAL OF CANCER, 2023, 189
  • [34] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Bottomley, Andrew
    Coens, Corneel
    Mierzynska, Justyna
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Puig, Susana
    Ascierto, Paolo A.
    Larkin, James
    Lorigan, Paul C.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    Eggermont, Alexander M. M.
    LANCET ONCOLOGY, 2021, 22 (05): : 655 - 664
  • [35] Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H.
    Arance, A. M.
    Cowey, L. C.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    de Pril, V.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)
    Michel, Pierre
    Boige, Valerie
    Andre, Thierry
    Aparicio, Thomas
    Bachet, Jean Baptiste
    Dahan, Laetitia
    Guimbaud, Rosine
    Lepage, Come
    Manfredi, Sylvain
    Tougeron, David
    Taieb, Julien
    Selves, Janick
    Le Malicot, Karine
    Di Fiore, Frederic
    Maillard, Emilie
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (03) : 305 - 307
  • [37] Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
    Eggermont, Alexander M. M.
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo Antonio
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Hosein, Fareeda
    de Pril, Veerle
    Kicinski, Michal
    Suciu, Stefan
    Testori, Alessandro
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : 1 - 10
  • [38] Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*
    Kennedy, Oliver John
    Glassee, Nina
    Kicinski, Michal
    Blank, Christian U.
    V. Long, Georgina
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Boers-Sonderen, Marye
    Giacomo, Anna Maria Di
    Eertwegh, Alfonsus J. M. van den
    Grob, Jean -Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Akkooi, Alexander C. J. van
    Gandini, Sara
    Buhrer, Emanuel
    Suciu, Stefan
    Robert, Caroline
    Eggermont, Alexander M. M.
    Mandala, Mario
    Lorigan, Paul
    Valpione, Sara
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [39] Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Inman, Robert D.
    Davis, John C., Jr.
    van der Heijde, Desiree
    Dickman, Laura
    Sieper, Joachim
    Kim, Sung Il
    Mack, Michael
    Han, John
    Visvanathan, Sudha
    Xu, Zhenhua
    Su, Benjamin
    Beutler, Anna
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3402 - 3412
  • [40] Efficacy and safety of meloxicam in the treatment of rheumatoid arthritis (RA): Results of a phase III double-blind, placebo controlled trial.
    Furst, DE
    Hall, DB
    Roszko, PJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S225 - S225
12345